Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tamantha K. Stutchbury"'
Publikováno v:
Research Evaluation. 28:51-62
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1629ea7aeaba149d75504e61d074fcf6
https://doi.org/10.1093/reseval/rvy039
https://doi.org/10.1093/reseval/rvy039
Autor:
Tamantha K. Stutchbury, Geoffrey M. Spinks, Victoria Traynor, Leanne Taylor, Lorna Moxham, Nicole L Michielin, Eliza de Vet, Victoria Ikutegbe
Publikováno v:
Australasian Journal on Ageing. 38
Objective To understand mobility issues not adequately serviced by assistive technology (AT). Methods A two-stage mixed-methods research project that forms the basis of future AT design and manufacture. Stage 1: a focus group comprising 46 participan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9253fc8a3d9778902cc6d20b56e38efb
https://doi.org/10.1111/ajag.12648
https://doi.org/10.1111/ajag.12648
Autor:
Tamantha K. Stutchbury, Kara L. Vine, Jeremy S. Chrisp, Philip Clingan, John B. Bremner, Marie Ranson, Julie M. Locke
Publikováno v:
Anti-Cancer Drugs. 22:24-34
5-Fluorouracil (5-FU) in combination with its synergistic biomodulator folinic acid maintains a pivotal position in cancer chemotherapy. However, clinical limitations such as phlebitis and catheter blockages persist with the administration of these d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e8b8522b6e4b2262bd8e15a21aa5074
https://doi.org/10.1097/cad.0b013e32833f6d22
https://doi.org/10.1097/cad.0b013e32833f6d22
Autor:
Philip Clingan, Kara L. Vine, John B. Bremner, Marie Ranson, Tamantha K. Stutchbury, Allan B. Gamble, Julie M. Locke
Publikováno v:
Anti-Cancer Drugs. 20:822-831
5-Fluorouracil in combination with its biomodulator folinic acid maintains a pivotal position in current anticancer treatment regimens. However, limitations in clinical management persist with the administration of these drugs. These limitations are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd82adbbcb7c0a6e77594e741ec20ab4
https://doi.org/10.1097/cad.0b013e32832fd78e
https://doi.org/10.1097/cad.0b013e32832fd78e
Autor:
David O. Irving, Tamantha K. Stutchbury, John Andrews, Marie Ranson, Fares Al-Ejeh, David R. Croucher, Gillian E. Stillfried, Matthew Links
Publikováno v:
Molecular cancer therapeutics. 6(1)
Tumor-associated urokinase plasminogen activator (uPA) is a critical marker of invasion and metastasis, has strong prognostic relevance, and is thus a potential therapeutic target. Experimental data published to date has established the proof-of-prin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb6fc64296047fca2d79eb15a99aee7
https://pubmed.ncbi.nlm.nih.gov/17237280
https://pubmed.ncbi.nlm.nih.gov/17237280